Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 241

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 241
---
                    300          
United Kingdom               -                     976                             976          
Other            141                               119                             260          
Total                        8,492                            1,095                     9,587   

                  Active Ingredients               Biopharmaceutical                Total      
-----------------------------------------------------------------------------------------------
                Year ended December 31, 2023                                                   
                Active Ingredients                Biopharmaceutical               Total        
                $                                 $                               $            
United States               3,416                            -                         3,416   
Germany                     3,563                            -                         3,563   
Other           164                                          -                    164          
Total                       7,143                            -                         7,143   

                  Active Ingredients               Biopharmaceutical                 Total      
------------------------------------------------------------------------------------------------
                Year ended December 31, 2022                                                    
                Active Ingredients                Biopharmaceutical               Total         
                $                                 $                               $             
United States                   8,600                        -                          8,600   
Germany                         4,563                        -                          4,563   
China                           1,326                        -                          1,326   
Other           83                                           -                    83            
Total                          14,572                        -                         14,572   
 
Revenues of approximately $7,593 (2023 – $6,337 and 2022 - $13,560) are derived from a single customer.
 
 
F-24
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 
Deferred revenue
 
The deferred revenue balance primarily relates to the advance consideration received in the form of non-refundable non-creditable upfront payment and milestone payments relating to list price approvals of Ghryvelin™ in the United Kingdom, Spain and Germany as per an exclusive licensing agreement for the commercialization of macimorelin (the “Licensed Product”) in the European Economic Area and the United Kingdom and an exclusive supply agreement for a period of ten years, subject to renewal, to supply such Licensed Product.
 
Revenue for this contract will be recognized based on units of Licensed Product supplied. The total units that the Company expects to supply pursuant to the Pharmanovia Agreement is an estimate, based on current projections and anticipated market demand, and therefore will be a significant judgement that